Ami Organics Limited Just Recorded A 13% EPS Beat: Here's What Analysts Are Forecasting Next

As you might know, Ami Organics Limited (NSE:AMIORG) just kicked off its latest yearly results with some very strong numbers. It was overall a positive result, with revenues beating expectations by 2.8% to hit ₹10b. Ami Organics reported statutory earnings per share (EPS) ₹19.81, which was a notable 13% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the current consensus from Ami Organics' six analysts is for revenues of ₹13.3b in 2026. This would reflect a huge 32% increase on its revenue over the past 12 months. Per-share earnings are expected to bounce 44% to ₹27.93. In the lead-up to this report, the analysts had been modelling revenues of ₹12.9b and earnings per share (EPS) of ₹26.19 in 2026. It looks like there's been a modest increase in sentiment following the latest results, withthe analysts becoming a bit more optimistic in their predictions for both revenues and earnings.

View our latest analysis for Ami Organics

Despite these upgrades,the analysts have not made any major changes to their price target of ₹1,310, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Ami Organics analyst has a price target of ₹1,570 per share, while the most pessimistic values it at ₹1,062. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The analysts are definitely expecting Ami Organics' growth to accelerate, with the forecast 32% annualised growth to the end of 2026 ranking favourably alongside historical growth of 23% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 10% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Ami Organics to grow faster than the wider industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Ami Organics' earnings potential next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. The consensus price target held steady at ₹1,310, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Ami Organics going out to 2028, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 1 warning sign for Ami Organics that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.